Navigation Links
Chimerix To Present At Therapeutic Area Partnerships Meeting
Date:11/26/2012

RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that President and Chief Executive Officer Kenneth I. Moch will present at the 2012 Therapeutic Area Partnerships meeting in Boston, MA.  His presentation will include an update on the company's clinical pipeline, including its lead development compound, CMX001, which was named by conference organizers a "Top 10 Project to Watch in Infectious Diseases." 

Mr. Moch will be presenting on Thursday, November 29 at 3:50 p.m. EST at the Westin Copley Place during the Infectious Diseases Projects to Watch session.  Therapeutic Area Partnerships is regarded as one of the industry's premier biopharmaceutical partnering event.  More information can be found on the meeting's web site:  www.tapartnerships.com.  

About Chimerix
Chimerix is developing novel oral antiviral therapeutics with the potential to improve outcomes for patients in multiple therapeutic areas, including transplant, oncology, acute care and global health. The Company's proprietary lipid technology has given rise to two clinical-stage lipid acyclic nucleoside phosphonates that have demonstrated the potential for enhanced activity and safety compared with currently approved drugs.

Chimerix's lead clinical-stage drug candidate, CMX001, is a novel, broad-spectrum, oral antiviral that inhibits double-stranded DNA (dsDNA) viruses, including cytomegalovirus (CMV), adenovirus (AdV), BK virus and herpes simplex virus. CMX001 has completed Phase 2 clinical development for the prophylaxis of CMV in hematopoietic stem cell transplant (HSCT) recipients and is in Phase 2 development for the preemption and treatment of AdV infection. To date, more than 800 patients have been dosed with CMX001 in controlled clinical trials and open-label treatment
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
2. Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
5. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
6. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
7. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
8. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
9. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
10. PRA Expert to Present at Pharmacovigilance Conference
11. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... Cambridge Healthtech Institute will host its fifth ... the Renaissance Waterfront Hotel in Boston, MA. The ... at the current strategies and innovations for optimizing bioprocesses ... in the field will reveal how their work has ... specificity and efficiency. , “In this age of rapid ...
(Date:5/16/2013)...  The registration deadline has been extended until May ... National Conference, the premier conference for bioscience financial officers. ... Hilton San Diego Bayfront. "We are ... want to make sure as many people as possible ... Roberts , Chief Financial Officer of Mast Therapeutics, ...
(Date:5/16/2013)... On average, developing a new drug takes over ... this investment, less than 10% of drugs make it ... trial design optimally structured to balance time, cost and ... Sax, Global Head of the Center for Drug Development ... and technology in upfront clinical trial planning and design ...
(Date:5/16/2013)... May 16, 2013 BioInformatics LLC New ... & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) ... of suppliers in the primary cells market continues to ... types are used most often, how satisfied scientists are ... size and anticipated growth rate. ,  , Additionally, ...
Breaking Biology Technology:The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3
... Oct. 27 Soligenix, Inc., (Soligenix or the Company) ... Inc., a late-stage biotechnology company, announced today that its ... overview highlighting recent developments at the BIO Investor Forum. ... 29, 2009 at 1:00 PM PDT at The Palace ...
... does a university introduce a cutting-edge academic model, ... (Logo: http://www.newscom.com/cgi-bin/prnh/20091027/NY99197LOGO ) , By ... required attendance) -- all in a first-year forum ... , Polytechnic Institute of New York University,s newest ...
... , Inc. (AIM: CRW.L), a leader in financial ... presentation at the Healthcare Financial Management Association,s (HFMA) Revenue ... IL. The session will be led by an industry ... of Revenue Integrity, Wendi Accardi of Advocate Health Care, ...
Cached Biology Technology:Soligenix to Present at 8th Annual BIO Investor Forum 2Soligenix to Present at 8th Annual BIO Investor Forum 3Soligenix to Present at 8th Annual BIO Investor Forum 4NYU-Poly Launches Unique Undergrad Forum on Invention, Innovation and Entrepreneurship 2NYU-Poly Launches Unique Undergrad Forum on Invention, Innovation and Entrepreneurship 3NYU-Poly Launches Unique Undergrad Forum on Invention, Innovation and Entrepreneurship 4Hospitals Improve Financial Performance by Identifying Exceptions to Best Practices 2Hospitals Improve Financial Performance by Identifying Exceptions to Best Practices 3
(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) ... The Endocrine Society (ENDO) 95th Annual Meeting in ... awards are meant to promote the entry of ... the mainstream of the basic science community and ... the ENDO 2013 Annual Meeting. , Awards are ...
(Date:5/16/2013)... have used ancient shorelines to predict the stability of today,s ... high shoreline from three million years ago, for example ... thought to be evidence of a high sea level due ... led many scientists to think that if the world,s largest ... just the same in our modern, progressively warming world. ...
(Date:5/16/2013)... the cellular layer lining the body,s blood vessels, ... nanometers in thickness, this super-tenuous structure routinely withstands ... to create a unique and highly dynamic barrier ... from the body,s circulatory system. , It,s also ... be physically breached to enable immune cells ...
Breaking Biology News(10 mins):World's biggest ice sheets likely more stable than previously believed 2Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
... the largest baby boom ever documented for the stock, with ... With typical annual averages of 50 to 100 million new ... puzzled by the huge increase and its ramifications for stock ... found one - healthy adults. In a study to ...
... technology, researchers led by a Weill Cornell Medical College scientist ... about half of all prostate cancers. Estrogen-linked signaling helps ... by a chromosomal translocation, which in turn results in the ... cancers harbor a common recurrent gene fusion, and we believe ...
... discovered that a fundamental building block in the ... identically, on a separate branch of the evolutionary ... originated at least 420 million years ago. ... gymnosperms, the group that includes conifers, ginkgos and ...
Cached Biology News:Healthy parents provide clues to survival of young haddock on Georges Bank 2Estrogen helps drive distinct, aggressive form of prostate cancer 2Estrogen helps drive distinct, aggressive form of prostate cancer 3When plants 'think' alike 2
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Zinc finger MYM-type protein 3 (Zinc finger protein 261) (DXS6673E protein). [Source:Uniprot/SWISSPROT;Acc:Q14202] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Biology Products: